BSH 2022 - 62nd British Society for Haematology Annual Scientific Meeting
Apr 03 - Apr 05, 2022 | ManchesterUK
LARVOL is not affiliated with 62nd British Society for Haematology Annual Scientific Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 52 abstracts linked to Trials
BSH22-OR16 - Bosutinib Versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia: Final 5-year Results From the BFORE Trial
BSH22-OR12 - Sudden or Cardiac Deaths on Ibrutinib-Based Therapy were associated with a prior History of Hypertension or Cardiac Disease and the use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
BSH22-PO57 - Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide + Rituximab (R2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
BSH22-PO64 - Efficacy of Mogamulizumab in Mycosis Fungoides by Patient Blood Involvement and Time to Response Analysis in Mycosis Fungoides and Sézary Syndrome: A post hoc analysis of the MAVORIC Study
BSH22-EP36 - Characterization and Outcomes in Patients with Mogamulizumab-Associated Skin Reactions in the MAVORIC Trial
BSH22-OR05 - Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results
BSH22-OR17 - Efficacy and safety of avapritinib as first-line treatment of patients with advanced systemic mastocytosis: Results of EXPLORER and PATHFINDER clinical study
BSH22-OR06 - Long-term Survival Benefit of Eculizumab Treatment in Patients With Paroxysmal Nocturnal Haemoglobinuria: Data From the International PNH Registry
BSH22-OR07 - Analysis Of Anaemia Persistence And Related Adverse Events In Patients With Paroxysmal Nocturnal Haemoglobinuria Treated With Pegcetacoplan
BSH22-OR10 - Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial
BSH22-OR35 - Pharmacokinetic/Pharmacodynamic Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia
BSH22-PO24 - Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT I and II Studies
BSH22-PO30 - Real-World Outcome of Patients with Myelofibrosis Treated with Ruxolitinib in the West of Scotland: A Retrospective Multicentre Analysis
BSH22-PO36 - Pegylated Interferon is an effective and well-tolerated cytroreductive agent in patients with myeloproliferative neoplasms aged over 60 years
BSH22-PO59 - Real-World Experience of Rapid Obinutuzumab Administration: Time to Change Obinutuzumab Infusion Rates